1 not yet recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Not yet recruiting 1 |
Follow Clinically Significant EBV DNAemia: new trials by email Literature Review of Clinically Significant EBV DNAemia trials Research Report on Clinically Significant EBV DNAemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation Rituximab (Arm A), Standard Post-Transplant Supportive Care - Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation | Not applicable | Not yet recruiting | Yang Donglin | 168 | 2026-07-09 | 2026-07-14 |
Rituximab (1)
Yang Donglin (1)
China (1)